These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 25768669)

  • 1. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC; Ahn SH; Kang Y; Clayman GL
    Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
    Mei J; Zhu X; Wang Z; Wang Z
    Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
    Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
    Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
    D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
    J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib regulating ERK signals pathway in gastric cancer cell.
    Juan LW; En LM; Hao L; Kai HY; Ju H
    Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
    Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.